eng Oriental Scientific Publishing Company Biosciences Biotechnology Research Asia 0973-1245 2015-08-15 12 2 1175 1179 2700 article Sara T. Alrashood 1 Fadilah S. Aleanizy 2 Fulwah Alqahtani 2 Ahad Abushal 3 Noor AlSalama 3 Ghada S. Hassan 4 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O.Box 2457, Riyadh 11451, Saudi Arabia. Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O.Box 2457, Riyadh 11451, Saudi Arabia. College of Pharmacy, King Saud University, P.O.Box 2457, Riyadh 11451, Saudi Arabia. Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, P.O.Box 35516, Mansoura, Egypt. Multiple Sclerosis (MS) is a chronic progressive autoimmune disease. It has complex symptoms and challenges. Patients suffer the most from the inconvenience and intolerability till the old injectable disease modifying therapies. Therefore our research is highlighting the scoop on the newly available treatment using the oral therapies proceeding from their chemical nature and structure to prove their superiority to the traditional ones in controlling MS progression. This can lead to an improvement inlife quality for MS patients with the enhanced tolerability for oral drugs that is best achieved by using Fingolimod that is considered as the first approved oral drug for this disease. https://www.biotech-asia.org/vol12no2/fingolimod-fty720-as-an-anti-multiple-sclerosis-oral-ultimate-therapy/ Multiple Sclerosis (MS); Autoimmune disease; Fingolimod; Therapy